Betthera s.r.o.

Company (SME)

betthera.com/Hradec Králové, Czech Republic

3 profile visits

About

Betthera is a consultancy based in Hradec Králové, Czech Republic, working in health economics, health technology assessment (HTA) and regulatory affairs since 2020. It helps developers of medical devices, in vitro diagnostics and digital health technologies build the evidence they need for CE marking, reimbursement and uptake in health systems.

Team

The team brings together health economists, including Prof. Petra Marešová (CEO) and Prof. Kamil Kuča (co-owner), and regulatory specialists led by Lukáš Peter, Ph.D. (co-owner, Regulatory Affairs Manager). Betthera has close links to academia and access to health data in Central and Eastern Europe.

Horizon Europe experience

Betthera is a partner in 13 Horizon Europe consortia: eCAP (capsule diagnostics of the gastrointestinal tract), PAINLESS (neuromodulation in palliative care), FORCE REPAIR (matrices for chronic wounds), IMPROVA (adolescent mental health), IN-ARMOR (antimicrobial resistance), NetZero AICT (climate-neutral CT imaging), ARTEMIS (virtual twins in fatty liver disease), TOXBOX (machine-learning toxicology platform), UltraSense (wearable sensing), NEOLIVER (bioprinted liver), NAP4DIVE (nanoparticle delivery across the blood-brain barrier), SmILE (smart implants for older adults) and VOLABIOS (volatile biomarkers of schizophrenia).

Betthera is looking for consortia preparing proposals for the 2027 Cluster 1 Health calls that need a partner for health economics, HTA, regulatory or market access tasks, especially projects developing medical devices, diagnostics, digital health or AI-based solutions.

Social media

Representatives

Project manager

Betthera s.r.o.

Regulatory Affairs Specialist and Client Partner

Betthera s.r.o.

Health Economics Specialist (HTA), CEO of Betthera

Betthera s.r.o.

Marketplace (2)

Project cooperation
Betthera as a partner for Cluster 1 Health 2027 proposals - Health economics, HTA and regulatory
Partner in 13 Horizon Europe projects, offering health economics, HTA and regulatory tasks for MedTech, diagnostics and digital health.
Partner seeks Consortium/Coordinator
Destination 6: HORIZON-HLTH-2027-02-IND-02-two-stage: Portable and versatile Point-of-care diagnostics
Destination 5: HORIZON-HLTH-2027-03-TOOL-02: Advancing bio-printing of living cells for regenerative medicine
Destination 3: HORIZON-HLTH-2027-02-DISEASE-01-two-stage: Innovative healthcare interventions for non-communicable diseases
Destination 2: HORIZON-HLTH-2027-01-ENVHLTH-MISSCLIMA-03: Tools and technologies to support health adaptation to climate change
Destination 5: HORIZON-HLTH-2027-03-TOOL-08: Towards the next generation of frontier Artificial Intelligence models for healthcare
Destination 3: HORIZON-HLTH-2027-01-DISEASE-06: Development of monoclonal antibodies to prevent and treat infections from Flaviviruses
Destination 3: HORIZON-HLTH-2027-01-DISEASE-08: Development of innovative antimicrobials against pathogens resistant to antimicrobials
Destination 3: HORIZON-HLTH-2027-02-DISEASE-14-two-stage: Clinical trials for advancing innovative interventions for neurodegenerative
Destination 1: HORIZON-HLTH-2027-01-STAYHLTH-01: Addressing disabilities through the life course to support independent living and inclusion
Destination 5: HORIZON-HLTH-2027-03-TOOL-04: Virtual Human Twins (VHTs) for integrated clinical decision support in prevention and diagnosis
Destination 6: HORIZON-HLTH-2027-01-IND-01: Development of cell-free protein synthesis platforms for discovery and/or production of biologicals
Destination 3: HORIZON-HLTH-2027-01-DISEASE-05: Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential
Destination 3: HORIZON-HLTH-2027-01-DISEASE-10: Prevention and management of chronic non-communicable diseases in children and young people (GACD)
Destination 4: HORIZON-HLTH-2027-01-CARE-02: Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
Destination 2: HORIZON-HLTH-2027-01-ENVHLTH-02: Integrating climate-related exposures into the human exposome and characterising its changes in response to climate change
Destination 3: HORIZON-HLTH-2027-01-DISEASE-07: Development of monoclonal antibodies to prevent and treat infections from Filo-, Nairo-, Phenui-, Picorna- and Toga viruses
Destination 5: HORIZON-HLTH-2027-02-TOOL-01-two-stage: Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
Author
Project manager at Betthera s.r.o.
Hradec Králové, Czech Republic
Project cooperation
Health economics, HTA and regulatory
Betthera is a Czech consultancy company in health economics, health technology assessment (HTA) and regulatory affairs for medical devices, in vitro diagnostics and digital health. We have registered for this event to join consortia preparing proposals.
Partner seeks Consortium/Coordinator
Destination 6: HORIZON-HLTH-2027-02-IND-02-two-stage: Portable and versatile Point-of-care diagnostics
Destination 3: HORIZON-HLTH-2027-02-DISEASE-01-two-stage: Innovative healthcare interventions for non-communicable diseases
Destination 2: HORIZON-HLTH-2027-01-ENVHLTH-MISSCLIMA-03: Tools and technologies to support health adaptation to climate change
Destination 5: HORIZON-HLTH-2027-03-TOOL-08: Towards the next generation of frontier Artificial Intelligence models for healthcare
Destination 3: HORIZON-HLTH-2027-01-DISEASE-06: Development of monoclonal antibodies to prevent and treat infections from Flaviviruses
Destination 3: HORIZON-HLTH-2027-01-DISEASE-08: Development of innovative antimicrobials against pathogens resistant to antimicrobials
Destination 3: HORIZON-HLTH-2027-02-DISEASE-14-two-stage: Clinical trials for advancing innovative interventions for neurodegenerative
Destination 1: HORIZON-HLTH-2027-01-STAYHLTH-01: Addressing disabilities through the life course to support independent living and inclusion
Destination 5: HORIZON-HLTH-2027-03-TOOL-04: Virtual Human Twins (VHTs) for integrated clinical decision support in prevention and diagnosis
Destination 6: HORIZON-HLTH-2027-01-IND-01: Development of cell-free protein synthesis platforms for discovery and/or production of biologicals
Destination 3: HORIZON-HLTH-2027-01-DISEASE-05: Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential
Destination 3: HORIZON-HLTH-2027-01-DISEASE-10: Prevention and management of chronic non-communicable diseases in children and young people (GACD)
Destination 4: HORIZON-HLTH-2027-01-CARE-02: Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
Destination 2: HORIZON-HLTH-2027-01-ENVHLTH-02: Integrating climate-related exposures into the human exposome and characterising its changes in response to climate change
Destination 3: HORIZON-HLTH-2027-01-DISEASE-07: Development of monoclonal antibodies to prevent and treat infections from Filo-, Nairo-, Phenui-, Picorna- and Toga viruses
Destination 5: HORIZON-HLTH-2027-02-TOOL-01-two-stage: Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
Author
Health Economics Specialist (HTA), CEO of Betthera at Betthera s.r.o.
Hradec Králové, Czech Republic